Sanofi's Dupixent Soars to New Heights, Offsetting Vaccine Sales Decline

Sanofi's blockbuster drug Dupixent has achieved a significant milestone, with quarterly sales surpassing €4 billion for the first time. This remarkable performance has helped the French pharmaceutical giant overcome a notable decline in vaccine sales, highlighting the drug's growing importance in Sanofi's portfolio.

Dupixent's Record-Breaking Performance

Dupixent, co-developed by Sanofi and Regeneron, generated €4.2 billion ($4.9 billion) in sales during the third quarter of 2025, marking a 26% year-over-year increase and an 8% sequential boost. The anti-inflammatory agent's success has been driven by expansion across all eight of its indications, including recent approvals for chronic obstructive pulmonary disorder (COPD), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP).

Brian Foard, Sanofi's specialty care chief, emphasized the drug's continued growth in foundational indications such as asthma, atopic dermatitis, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps. Notably, Foard highlighted COPD as the "fastest respiratory indication as far as growth rate goes," following its launch a year ago.

The momentum behind Dupixent is further evidenced by a 32% increase in the number of patients being treated worldwide compared to the previous year, according to Chief Financial Officer François Roger.

Vaccine Sales Decline Amid Challenging Market Conditions

While Dupixent's performance has been stellar, Sanofi reported an 8% year-over-year decline in vaccine sales, totaling €3.4 billion ($3.9 billion) for the quarter. The company attributed this downturn to lower vaccination rates and what Roger described as "negative buzz" surrounding vaccines in general.

Thomas Triomphe, Sanofi's vaccines chief, noted that the early weeks of the flu season have shown vaccination rates "on the soft side," particularly in the United States. This trend suggests that the company's heavy reliance on flu vaccines may continue to pose challenges in the near term.

Overall Financial Performance and Outlook

Despite the setback in vaccine sales, Sanofi's overall performance remained strong. The company reported total sales of €12.4 billion ($14.4 billion) for the quarter, representing a 7% year-over-year increase. This result has led Sanofi to reaffirm its annual sales guidance, projecting high-single-digit growth compared to the previous year's 8.6% revenue boost.

The market responded positively to Sanofi's quarterly results, with the company's share price increasing by 4% in mid-morning trading following the announcement.

As Dupixent continues to exceed expectations and expand its reach across multiple indications, it has solidified its position as a cornerstone of Sanofi's growth strategy. With year-to-date sales of €11.5 billion ($13.4 billion), the drug is on track to surpass last year's total of €13.1 billion, further cementing its status as a pharmaceutical industry powerhouse.